health insurance landscape creates both the opportunity and the constraint: commercial insurance covering GLP-1 for diabetes generates large, well-reimbursed prescription volumes, but coverage for obesity indications varies widely, with Medicare explicitly prohibited from covering weight loss drugs until the Treat and Reduce Obesity Act passes a legislative gap that excludes tens of millions of Medicare beneficiaries from covered GLP-1 obesity access
Many patients have struggled for years before seeking help, often feeling discouraged by programs that did not reflect the true complexity of their challenges
Its all about looking at the whole picture and not just one number on a lab report
But its size and matched comparison design make the findings more reliable than earlier isolated reports of GLP-1s and hair loss, says Friedman
Side Effects Comparison When comparing the side effects of compounded Semaglutide and Ozempic, it's notable that they share a very similar, if not identical, profile (3,4,5)